Huntington’s Gene Therapy And Rare Disease Pipeline Will Reshape Long Term Outcomes

Catalysts

About uniQure

uniQure develops gene therapies targeting serious neurological and rare metabolic diseases.

What are the underlying business or industry changes driving this perspective?

• Compelling AMT-130 Huntington's disease data, including 75% slowing of disease progression on cUHDRS and 60% on total functional capacity at 3 years with supportive neurofilament light biomarker trends, creates a potential foundation for a first in class therapy that could expand addressable revenue as payers and regulators become more familiar with one time gene therapies.
• Growing global focus on rare disease treatment, together with uniQure's intention to engage regulators in the US, EU and UK on AMT-130, positions the company to potentially access multiple geographies over time. This would directly affect long term revenue scale and earnings power.
• Pipeline breadth in neurological and metabolic indications, including AMT-260 in mesial temporal lobe epilepsy and AMT-191 in Fabry disease with early signs of clinical activity and enzyme replacement withdrawal, creates several shots on goal that could diversify future revenue and support more resilient margins.
• The move toward one time, disease modifying therapies in chronic and high burden conditions, reflected in early Fabry and epilepsy data and strong Huntington's community engagement, supports a model where higher upfront pricing can be matched to meaningful clinical benefit. There is potential for improved net margins if commercial infrastructure is leveraged across multiple programs.
• Cash, cash equivalents and investment securities of US$694.2 million as of 30 September 2025, together with guidance that this funds operations into 2029, give uniQure time to progress AMT-130 regulatory discussions and advance key pipeline trials without near term financing pressure. This supports visibility on research investment, potential future revenue growth and path to earnings leverage.

Assumptions

This narrative explores a more optimistic perspective on uniQure compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming uniQure's revenue will grow by 235.6% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from -1492.9% today to 27.8% in 3 years time.
• The bullish analysts expect earnings to reach $165.6 million (and earnings per share of $2.17) by about January 2029, up from $-235.1 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $-257.4 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 51.5x on those 2029 earnings, up from -6.7x today. This future PE is greater than the current PE for the US Biotechs industry at 21.1x.
• The bullish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.21%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Regulatory uncertainty around AMT-130 has increased after the FDA signaled that Phase I/II data using an external control may no longer be sufficient for a BLA. This could lead to delays, the need for additional costly trials, or changes in study design, putting at risk the timing and scale of potential AMT-130 revenue and extending the period of losses on earnings.
• uniQure is committing significant resources to Huntington's disease ahead of clear regulatory visibility, including costs tied to BLA preparation and potential commercialization. If approval is delayed or the label is narrower than expected, the heavier research and development and selling, general and administrative spending could weigh on net margins and earnings for longer than bullish expectations assume.
• The pause in enrollment for AMT-162 in ALS after a serious adverse event related to dose-limiting toxicity highlights safety concerns with certain delivery routes. If similar issues emerge in other programs or regulators tighten their stance on gene therapy risk, this could limit the breadth of the pipeline that ultimately reaches market and reduce future revenue diversification and margin resilience.
• Several pipeline assets, including AMT-260 for mesial temporal lobe epilepsy and AMT-191 for Fabry disease, are still at early clinical stages, with key updates not expected until the first half of 2026. Any less favorable efficacy or safety data relative to current expectations could shrink long term addressable revenue and prolong the period before earnings move toward profitability.
• The business is currently small scale, with quarterly revenue of US$3.7 million against research and development expenses of US$34.4 million and selling, general and administrative expenses of US$19.4 million. If regulatory paths lengthen or additional capital is raised in future years, shareholders could face further dilution while revenue, net margins and earnings remain under pressure.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for uniQure is $90.71, which represents up to two standard deviations above the consensus price target of $55.44. This valuation is based on what can be assumed as the expectations of uniQure's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $96.36, and the most bearish reporting a price target of just $33.36.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $595.5 million, earnings will come to $165.6 million, and it would be trading on a PE ratio of 51.5x, assuming you use a discount rate of 7.2%.
  
• Given the current share price of $25.32, the analyst price target of $90.71 is 72.1% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.